EUVIMEDOpdag EUVIMED
FallberichtOpen access · CC BY 4.0

Psychosis, Catatonia and Tachypnoea Following Paliperidone Palmitate 3‐Monthly Injection Error: Case Report

Milla R McLean iD, Lee Hanley iD, M J Yoo iD

Case Reports in Psychiatry · 2026-01 · 2026 (1)

DOI: 10.1155/crps/4635562 ↗

At a glance

Fallbericht in Case Reports in Psychiatry, published online on 2026-08-18. Written by Milla R McLean and 2 co-authors. Institution: Department of Psychiatry, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, thermh.org.au. 20 references. The full text is freely available (open access, CC BY 4.0). Funded by: University of Melbourne.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Paliperidone palmitate 3‐monthly (PP3M) is a long‐acting Injection (LAI) formulation of the anti‐psychotic medication paliperidone, also known as 9‐hydroxyrisperidone (9‐OH‐RIS). There is a notable absence of clinical guidelines or case reports pertaining to PP3M overdose and management of incorrect dosing. Patient Concerns and Clinical Findings We present the first reported case of PP3M administered at 1 monthly intervals for three consecutive months in the community setting and describe the inpatient management of psychosis and catatonia occurring in the context of this overdose. Diagnoses, Interventions and Outcomes During this patient’s admission to an inpatient psychiatric unit, our team, involving specialised pharmacy, navigated the acute management of psychosis in the context of PP3M overdose in the absence of published guidelines. We share the use of electroconvulsive therapy (ECT) and oral lorazepam in managing this patient’s acute psychosis and catatonia presentation and provide a rationale for the timing of safe recommencement of paliperidone oral medication. The patient was safely discharged home.

Conclusions

We highlight the need for LAI overdose guidelines as an important area for review and development of clinical guidelines as we see increasing use of paliperidone palmitate 1‐monthly (PP1M), PP3M, and paliperidone palmitate 6‐monthly injection (PP6M) in the community.

Subjects

Author keywords

anti-psychoticcase reportlong-acting injectionmedication errorpaliperidone palmitate

Authors and institutions

  • Department of Psychiatry, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, thermh.org.au.
  • Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia, unimelb.edu.au.
  • Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia, unimelb.edu.au.

ORCID profiles: Milla R McLean, Lee Hanley, M J Yoo

Funding

  • University of Melbourne

Cite

APA

McLean, M. R., Hanley, L., & Yoo, M. J. (2026). Psychosis, Catatonia and Tachypnoea Following Paliperidone Palmitate 3‐Monthly Injection Error: Case Report. Case Reports in Psychiatry, 2026(1). https://doi.org/10.1155/crps/4635562

Vancouver

McLean MR, Hanley L, Yoo MJ. Psychosis, Catatonia and Tachypnoea Following Paliperidone Palmitate 3‐Monthly Injection Error: Case Report. Case Reports in Psychiatry. 2026;2026(1). doi:10.1155/crps/4635562

BibTeX
@article{McLean2026,
  author = {McLean, Milla R and Hanley, Lee and Yoo, M J},
  title = {Psychosis, Catatonia and Tachypnoea Following Paliperidone Palmitate 3‐Monthly Injection Error: Case Report},
  journal = {Case Reports in Psychiatry},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crps/4635562}
}
Start for free →